| 16477-2 |
Borrelia burgdorferi Ab |
PrThr |
Body fld |
Pt |
Ord |
|
|
ACTIVE |
Borrelia burgdorferi Ab [Presence] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16477-2 |
|
|
|
|
Both |
|
|
|
0 |
B burgdor Ab Fld Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; B/F; Bb; BF; bod; Bodies; Body fluid; Body fluid, unsp; Burgdorf; Fl; Fld; FLU; Fluid; ID; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16478-0 |
Borrelia burgdorferi Ab.IgA |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Borrelia burgdorferi IgA Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16478-0 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor IgA Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; Bb; Burgdorf; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin A; Immunoglobulin A; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16479-8 |
Borrelia burgdorferi Ab.IgA |
PrThr |
CSF |
Pt |
Ord |
IA |
|
ACTIVE |
Borrelia burgdorferi IgA Ab [Presence] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16479-8 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor IgA CSF Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; Bb; Burgdorf; Cerebral spinal fluid; Cerebrospinal Fl; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin A; Immunoglobulin A; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; SUDS |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1648-5 |
Tuberculosis reaction wheal^3D post 5 TU ID |
Diam |
Skin |
Pt |
Qn |
|
|
ACTIVE |
Tuberculosis reaction wheal [Diameter] --3 days post 5 TU intradermal |
|
MIN |
DefinitionDescription |
|
|
mm |
|
|
|
|
|
|
CHALSKIN |
|
1648-5 |
|
|
|
|
Observation |
|
|
|
0 |
TB Wheal 3D p 5 TU Diam |
|
|
|
Y |
|
3D p 5 TU; After; Dermatologic; Diameter; Epidermis; Identifier; Integument; Intermediate strength PPD; Intradermal; Point in time; PPD; PST; Purified protein derivative skin test; Purified protein derivative test; QNT; Quan; Quant; Quantitative; Random; React; Rx wheal; Rxn; Skin test; SKIN TESTS; Skn; TB; TB skin test; TB Wheal; TST; Tubeculin Units |
2.73 |
1 |
|
|
|
|
|
|
|
mm |
|
|
|
0 |
| 16480-6 |
Borrelia burgdorferi Ab.IgG |
PrThr |
Ser/Plas |
Pt |
Ord |
IA |
|
ACTIVE |
Borrelia burgdorferi IgG Ab [Presence] in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16480-6 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor IgG SerPl Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; Bb; Burgdorf; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.; Updated system from Ser to Ser/Plas |
0 |
| 16481-4 |
Borrelia burgdorferi Ab.IgG |
ACnc |
Body fld |
Pt |
Qn |
IA |
|
ACTIVE |
Borrelia burgdorferi IgG Ab [Units/volume] in Body fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16481-4 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor IgG Fld IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; B/F; Bb; BF; bod; Bodies; Body fluid; Body fluid, unsp; Burgdorf; EIA; ELFA; ELISA; Enzyme immunoassay; Fl; Fld; FLU; Fluid; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; SUDS |
2.73 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16482-2 |
Borrelia burgdorferi Ab.IgM |
ACnc |
Body fld |
Pt |
Qn |
IA |
|
ACTIVE |
Borrelia burgdorferi IgM Ab [Units/volume] in Body fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16482-2 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor IgM Fld IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; B/F; Bb; BF; bod; Bodies; Body fluid; Body fluid, unsp; Burgdorf; EIA; ELFA; ELISA; Enzyme immunoassay; Fl; Fld; FLU; Fluid; IAA; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; SUDS |
2.73 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16483-0 |
Borrelia hermsii |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Borrelia hermsii [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16483-0 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
B hermsii Spec Ql Cult |
|
|
|
|
|
B hermsii; C&S; Cult; Cultures; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Relapsing fever; Screen; Spec; To be specified in another part of the message; Unspecified |
2.69 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16484-8 |
Boysenberry Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Boysenberry IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
16484-8 |
|
|
|
|
Both |
|
|
|
0 |
Boysenberrry IgE Qn |
|
|
|
Y |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Boysenberrry; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.42 |
1.0l |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
| 16485-5 |
Bromodiphenhydramine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Bromodiphenhydramine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16485-5 |
|
|
|
|
Both |
|
|
|
0 |
Bromodiphenhyd Ur-mCnc |
|
|
|
Y |
|
Amrodyl; Bromazine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 16486-3 |
Brucella abortus Ab.IgA+IgG+IgM |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Brucella abortus IgA+IgG+IgM Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16486-3 |
|
|
|
|
Both |
|
|
|
0 |
B abortus IgA+IgG+IgM Ser-aCnc |
|
|
|
Y |
|
Abort; ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B abortus; Bangs disease; Bovine brucellosis; Bruc; Brucellosis; Contagious abortion; ID; Immune globulin A; Immune globulin G; Immune globulin M; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Undulant fever |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16487-1 |
Brucella abortus Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
Aggl |
|
ACTIVE |
Brucella abortus IgG Ab [Units/volume] in Serum by Agglutination |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16487-1 |
|
Aggl |
|
|
Both |
|
|
|
0 |
B abortus IgG Ser Aggl-aCnc |
|
|
|
Y |
|
Abort; ABS; Aby; Agg; Agglut; Agglutination; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B abortus; Bangs disease; Bovine brucellosis; Bruc; Brucellosis; Contagious abortion; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Undulant fever |
2.73 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16488-9 |
Brucella abortus Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
Comp fix |
|
ACTIVE |
Brucella abortus IgG Ab [Units/volume] in Serum by Complement fixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16488-9 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
B abortus IgG Ser CF-aCnc |
|
|
|
Y |
|
Abort; ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B abortus; Bangs disease; Bovine brucellosis; Bruc; Brucellosis; CF; Comp fixation; Compfix; Complement fixation; Contagious abortion; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Undulant fever |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16489-7 |
Brucella melitensis Ab |
ACnc |
Ser |
Pt |
Qn |
LA |
|
ACTIVE |
Brucella melitensis Ab [Units/volume] in Serum by Latex agglutination |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16489-7 |
|
LA |
|
|
Both |
|
|
|
0 |
B melitensis Ab Ser LA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B melitensis; Bruc; Brucellosis; ID; Infectious Disease; InfectiousDisease; LAT; Latex agglutination; Malta fever; Mediterranean fever; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Undulant fever |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 1649-3 |
Calcitriol |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Calcitriol [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHEM |
|
1649-3 |
|
|
|
|
Both |
|
|
|
0 |
1,25(OH)2D3 SerPl-mCnc |
|
|
|
Y |
|
1,25(OH)2D3; 1,25-Calcitriol; 1,25-Dihydroxycholecalciferol; 1,25-Dihydroxyvitamin D; 1,25-Dihydroxyvitamin D3; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
303 |
| 16490-5 |
Brucella suis Ab |
ACnc |
Ser |
Pt |
Qn |
LA |
|
ACTIVE |
Brucella suis Ab [Units/volume] in Serum by Latex agglutination |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
16490-5 |
|
LA |
|
|
Both |
|
|
|
0 |
B suis Ab Ser LA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; B suis; Bruc; Brucellosis; ID; Infectious Disease; InfectiousDisease; LAT; Latex agglutination; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 16491-3 |
Brush border Ab |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Brush border Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
16491-3 |
|
IF |
|
|
Both |
|
|
|
0 |
Brush border Ab Ser Ql IF |
|
|
|
|
|
ABBA; ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; BBA; FA; Fluorescent antibody; Fluoresent; Gastro; Gastroenterology; GI; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Kidney; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; Serology; Serum; SR; Time Resolved Fluorescence; TRF |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 16492-1 |
Bufotenine |
ACnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
Bufotenine [Units/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16492-1 |
|
|
|
|
Both |
|
|
|
0 |
Bufotenine Ur-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Bufotenin; Cebilcin; DRUG/TOXICOLOGY; Drugs; Mappine; NN-Dimethylserotonin; Point in time; QNT; Quan; Quant; Quantitative; Random; Toad hallucinogen; UA; UR; Urn |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16493-9 |
Bufotenine |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Bufotenine [Units/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16493-9 |
|
|
|
|
Both |
|
|
|
0 |
Bufotenine SerPl-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Bufotenin; Cebilcin; DRUG/TOXICOLOGY; Drugs; Mappine; NN-Dimethylserotonin; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Toad hallucinogen |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16494-7 |
Bumetanide |
ACnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
Bumetanide [Units/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16494-7 |
|
|
|
|
Both |
|
|
|
0 |
Bumetanide Ur-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Bumex; Burinex; Butinat; DRUG/TOXICOLOGY; Drugs; Farmadiuril; Fontego; Fordiuran; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16495-4 |
Buprenorphine |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Buprenorphine [Units/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16495-4 |
|
|
|
|
Both |
|
|
|
0 |
Buprenorphine SerPl-aCnc |
|
|
|
Y |
|
Addiction; Arbitrary Concentration; BU; BUP; Bupe; Buprenex; buprenorphine HCI; Buprex; Butrans; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Finobrin; Illicit; Norspan; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; Prefin; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Suboxone; Subutex; Temgesic |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16496-2 |
Buprenorphine |
ACnc |
Urine |
Pt |
Qn |
|
|
DISCOURAGED |
Buprenorphine [Units/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16496-2 |
|
|
|
|
Both |
|
|
|
0 |
Buprenorphine Ur-aCnc |
|
|
|
Y |
|
Addiction; Arbitrary Concentration; BU; BUP; Bupe; Buprenex; buprenorphine HCI; Buprex; Butrans; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Finobrin; Illicit; Norspan; Point in time; PotentialForAbuse; Prefin; QNT; Quan; Quant; Quantitative; Random; Suboxone; Subutex; Temgesic; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16497-0 |
Butabarbital |
MCnc |
Gast fld |
Pt |
Qn |
|
|
ACTIVE |
Butabarbital [Mass/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16497-0 |
|
|
|
|
Both |
|
|
|
0 |
Butabarbital Gast-mCnc |
|
|
|
Y |
|
Addiction; Barbiturate; Butabarb; Butabarbitl; Butisol; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GAST; Gastric contents; Gastric fluid; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 16498-8 |
Butalbital |
ACnc |
Gast fld |
Pt |
Qn |
|
|
DISCOURAGED |
Butalbital [Units/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16498-8 |
|
|
|
|
Both |
|
|
|
0 |
Butalbital Gast-aCnc |
|
|
|
Y |
|
Addiction; Allylbarbital; Allylbarbituric acid; Arbitrary concentration; Barbiturate; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fiorinal; GAST; Gastric contents; Gastric fluid; Illicit; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 16499-6 |
Butorphanol |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Butorphanol [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16499-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Butorphanol Ur Cfm-mCnc |
|
|
|
Y |
|
Addiction; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Stadol; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
